Contact
searchSearch
HMP Global
Login
Quiz

Efficacy and Safety of Tazemetostat for R/R DLBCL and FL

08/25/2025

Related Content

News
Epcoritamab Plus R-CHOP Improves Progression-Free Survival Over R-CHOP Alone in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma
10/08/2026
Emily Estrada
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3...
10/08/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
Umberto Vitolo, MD
Podcasts
Tafasitamab Plus Lenalidomide Improves Frontline Outcomes in High-Risk Diffuse Large B-Cell Lymphoma
07/08/2026
Umberto Vitolo, MD
Umberto Vitolo, MD, discusses results from the phase 3 FrontMIND trial showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with newly diagnosed high-risk diffuse large B-cell...
Umberto Vitolo, MD, discusses results from the phase 3 FrontMIND trial showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with newly diagnosed high-risk diffuse large B-cell...
Umberto Vitolo, MD, discusses...
07/08/2026
Oncology
Marco Ruella, MD
Videos
Ten-Year Tisagenlecleucel Outcomes Highlight Lasting Remissions in Relapsed or Refractory B-Cell Lymphoma
07/01/2026
Marco Ruella, MD
Marco Ruella, MD, discusses 10-year follow-up data showing that tisagenlecleucel produced durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, supporting the long-term curative...
Marco Ruella, MD, discusses 10-year follow-up data showing that tisagenlecleucel produced durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, supporting the long-term curative...
Marco Ruella, MD, discusses...
07/01/2026
Oncology

Recent News

FDA Approval
FDA Expands Nogapendekin Alfa Inbakicept Plus Bacillus Calmette-Guérin Approval to Include High-Grade Papillary-Only Bladder Cancer
10/14/2026
Emily Estrada
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication...
10/14/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Advanced Desmoid Tumors
10/09/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial...
10/09/2026
Oncology
News
Iberdomide Plus Daratumumab and Dexamethasone Significantly Improves PFS in Relapsed or Refractory Multiple Myeloma
10/08/2026
Stephanie Holland
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3...
10/08/2026
Oncology
News
Cytarabine Induction Followed by Azacitidine and Lenalidomide Shows Activity in Very-High-Risk Myelodysplastic Syndromes
10/08/2026
Emily Estrada
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study...
10/08/2026
Oncology
News
Acute Myeloid Leukemia Transformation Emerges as Strongest Predictor of Relapse After Allogenic-HSCT in Myelodysplastic Syndromes
10/08/2026
Emily Estrada
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of...
10/08/2026
Oncology
News
Epcoritamab Plus R-CHOP Improves Progression-Free Survival Over R-CHOP Alone in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma
10/08/2026
Emily Estrada
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3...
10/08/2026
Oncology
News
SurVaxM Shows Survival Signal in Newly Diagnosed Glioblastoma, With Significant Benefit in Younger Patients
10/07/2026
Emily Estrada
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b...
10/07/2026
Oncology
FDA Approval
FDA Approves Tucatinib Plus Trastuzumab and Pertuzumab for Maintenance Treatment of HER2-Positive Advanced Breast Cancer
10/07/2026
Stephanie Holland
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the...
10/07/2026
Oncology
FDA Approval
FDA Expands Pirtobrutinib to First-Line Treatment of CLL/SLL Without 17p Deletion
10/02/2026
Stephanie Holland
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN...
10/02/2026
Oncology
News
Risvutatug Rezetecan More Than Doubles Response and Significantly Extends Survival in Patients With Relapsed Small Cell Lung Cancer
09/29/2026
Emily Estrada
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3...
09/29/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use